Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Venetoclax is an oral, small-molecule targeted drug that restores the apoptosis ···【more】
Release date：2024-08-14Recommended：258
Venetoclax is the world's first approved selective inhibitor of Bcl-2 that i···【more】
Release date：2024-08-14Recommended：274
Pemigatinib is a targeted therapy drug that is of great significance in the trea···【more】
Release date：2024-08-14Recommended：226
Pemigatinibis primarily used for the treatment of adult patients with advanced, ···【more】
Release date：2024-08-14Recommended：218
Pemigatinibhas demonstrated significant efficacy in the treatment of cholangioca···【more】
Release date：2024-08-14Recommended：252
Pemigatinib is used in adults to treat bile duct cancer that has spread to other···【more】
Release date：2024-08-14Recommended：233
Pemigatinib is an effective treatment for advanced or metastatic cholangiocarcin···【more】
Release date：2024-08-14Recommended：215
Pemigatinib leads to constitutive activation of FGFR by activating FGFR amplific···【more】
Release date：2024-08-14Recommended：223
Venetoclax is a targeted anti-cancer drug used to treat certain types of blood c···【more】
Release date：2024-08-13Recommended：271
Venetoclax is a novel oral small molecule drug that targets the BCL-2 protein to···【more】
Release date：2024-08-13Recommended：364
Venetoclax is a small molecule drug that targets BCL-2 and is able to promote no···【more】
Release date：2024-08-13Recommended：256
Venetoclax is an oral anticancer drug targeting BCL-2 that promotes apoptosis of···【more】
Release date：2024-08-13Recommended：197
